New brain scan agent helps tell tumor from treatment side effects

NCT ID NCT06743100

NO_LONGER_AVAILABLE Diagnosis Sponsor: Telix Pharmaceuticals (Innovations) Pty Limited Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This program gave patients with glioma (a type of brain tumor) access to a special imaging agent called 18F-FET. It was used with PET scans to help doctors tell the difference between actual tumor growth and changes caused by previous treatments. The goal was to improve treatment decisions for patients aged 3 and older with unclear MRI results.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GLIOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

brain glioma glioma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

GLIOMA (ANY GRADE) IN THE BRAIN

Contacts and locations

Locations

CU Anschutz / University of Colorado

Aurora, Colorado, 80045, United States
Dana Farber Cancer Institute

Boston, Massachusetts, 02215, United States
Johns Hopkins Baltimore

Baltimore, Maryland, 21205, United States
Kettering Health Main Campus

Kettering, Ohio, 45429, United States
MSKCC (Memorial Sloan Kettering Cancer Center)

New York, New York, 10065, United States
Northwestern University

Chicago, Illinois, 60611, United States
Thomas Jefferson University

Philadelphia, Pennsylvania, 19107, United States
UC Irvine

Orange, California, 92868, United States
University Pennsylvania

Philadelphia, Pennsylvania, 19104, United States
University Wisconsin Madison

Madison, Wisconsin, 53705-2275, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.